Extended-release granule formulations containing diclofenac sodium were prepared by wet granulation of Eudragit® LI00 and Eudragit® NM 30D polymers. The drug release was examined in phosphate buffer (pH 6.8). The formulations allowed 100 % released drug by 720 min. The granules were evaluated with respect to their anti-inflammatory and ulcerogenic activity in rats. Eudragit® LlOO/Eudragif3 NM 30D granules provide a significant and prolonged anti-inflammatory effect and also significantly reduce (52-74 %) the gastric lesion index.
Keywords: Eudragit L100, Eudragit NM 30D, Anti-inflammatory effect, Diclofenac sodium, Ulcerogenic activity